Sarepta Therapeutics
Yahoo Finance • 3 months ago
Exploring TeraWulf And Two Other High Growth Tech Stocks
The market is up 1.2% over the last week and has risen 30% over the past 12 months, with earnings forecast to grow by 15% annually. In this favorable environment, identifying high-growth tech stocks like TeraWulf can be crucial for investo... Full story
Yahoo Finance • 4 months ago
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
CAMBRIDGE, Mass., August 30, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Mor... Full story
Yahoo Finance • 5 months ago
This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes
This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes During earnings season, big banks are often among the first companies to unveil their quarterly financial results. But rather t... Full story
Yahoo Finance • 7 months ago
Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?
We recently compiled the list of the 10 Best Fast Growth Stocks To Buy according to the hedge funds using the latest sentiment data. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands agai... Full story
Yahoo Finance • 7 months ago
Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) just released its quarterly report and things are looking bullish. It was a solid earnings report, with revenues and statutory earnings per share (EPS) both coming in strong. Revenues were 10% highe... Full story
Yahoo Finance • 8 months ago
10 Unstoppable Stocks That Will Make You Richer
In this article, we discuss the 10 unstoppable stocks that will make you richer. To skip the detailed analysis of the economy and market, go directly to the 5 Unstoppable Stocks That Will Make You Richer. On April 12, the week closed out... Full story
Yahoo Finance • 9 months ago
Billionaire Ray Dalio and Insiders Love These 10 Stocks
In this article, we will take a detailed look at Billionaire Ray Dalio and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Ray Dalio and Insiders Love These 5 Stocks. Investors are on tente... Full story
Yahoo Finance • 9 months ago
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcom... Full story
Yahoo Finance • 10 months ago
Decoding Sarepta Therapeutics Inc (SRPT): A Strategic SWOT Insight
Strengths: Proprietary RNA-targeted technology platforms and a robust pipeline of gene therapies. Weaknesses: Ongoing operating losses and intense competition in the biopharmaceutical industry. Opportunities: Expansion of commercial distri... Full story
Yahoo Finance • 11 months ago
Sarepta Rebounded. Its Gene Therapy Is Back on Course.
The future of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy looked grim two months ago. There’s been a 180 since. Continue reading... Full story
Yahoo Finance • 12 months ago
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., January 02, 2024--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 42nd Annual J.P. Morgan H... Full story
Yahoo Finance • 12 months ago
13 High Growth Healthcare Stocks to Buy
In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story
Yahoo Finance • 12 months ago
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Application includes request for Priority Review from the US FDA Sarepta has also submitted the EMBARK postmarketing requirement to the FDA seeking conversion of the ELEVIDYS accelerated approval to traditional approval CAMBRIDGE, Mass.,... Full story
Yahoo Finance • last year
11 Best Upside Stocks To Buy Right Now
In this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has alw... Full story
Yahoo Finance • last year
13 Stocks Insiders are Buying Now
In this article, we will take a look at the 13 stocks insiders are buying now. To see more such companies, go directly to 5 Stocks Insiders are Buying Now. With the end of 2023 now in sight, many can say with confidence that the much-drea... Full story
Yahoo Finance • last year
SRPT LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting fro... Full story
Yahoo Finance • last year
SRPT INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPT
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from... Full story
Yahoo Finance • last year
Analysts on Wall Street Lower Ratings for These 10 Stocks
In this article, we will discuss the 10 stocks recently downgraded by analysts. If you want to see more such stocks on the list, you can directly visit Analysts on Wall Street Lower Ratings for These 5 Stocks. Headlines from the financial... Full story
Yahoo Finance • last year
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
ELEVIDYS net product revenues for the quarter totaled $69.1 million Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2023 totaled $331.8 million Net product revenues for the third quar... Full story
Yahoo Finance • last year
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
Investors looking to earn outsized returns over long periods (which describes most investors) would do well to consider shares of innovative companies such as CRISPR Therapeutics (NASDAQ: CRSP), Sarepta Therapeutics (NASDAQ: SRPT), and Dex... Full story
